Combretastatin A4

For research use only.

Catalog No.S7783

3 publications

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

Size Price Stock Quantity  
EUR 95 In stock
EUR 390 In stock
EUR 979 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Combretastatin A4 has been cited by 3 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.
Targets
β-tubulin [1]
0.4 μM(Kd)
In vitro

Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively.[1] [2] 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 NEn2NnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfUZ|BbS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hW0uPRVytOUBu\Wyjbn;tZUBk\WyuIHzpcoV{NCCHREWwQVMvODCHLUC4JO69VQ>? MXWxPFc2OzVy
A-549 MlfWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3:2U2N6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJGEuPTR7IHz1coch[2G{Y3nuc41iKGOnbHygcIlv\XNuIFXEOVA:OS5{MFWtNFYh|ryP NF73UmEyQDd3M{Ww
MCF-7 NXf4U|UxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUTCcFV1S3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hVUOILUegZpJm[XO2IHPhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUOuPFBGNTB4IN88US=> NVjw[2ZtOTh5NUO1NC=>
HT-29 NFzwVodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUfBcIt7S3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hUFRvMkmgZ49td25iYXTlco9k[XKlaX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjJyRT2wOkDPxE1? MoDFNVg4PTN3MB?=
MLM melanoma cell MlW1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnXGR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gUWxOKG2nbHHuc41iKGOnbHygcIlv\XNuIFXEOVA:OS52MFWtNFYh|ryP NWDGT5hsOTh5NUO1NC=>
M14 NXPtUmFFS3m2b4TvfIlkcXS7IHHzd4F6 NVX4VIVwUW5idnn0do8h[3m2b4TvfIlkKGGldHn2bZR6KHejczD0[ZN1\WRiYXfhbY5{fCCqdX3hckBu\Wyjbn;tZUBk[W6lZYKgLG0yPCliY3XscEBtcW6nLDDHTVUxRTBwMECwNUDPxE1? MkXJNVI4Ojl4NEC=
SK-OV3 MUHDfZRwfG:6aXPpeJkh[XO|YYm= M1riVWlvKH[rdILvJIN6fG:2b4jpZ{Bi[3Srdnn0fUB1\XO2ZXSgZYdicW6|dDDoeY1idiCxdnHybYFvKGOjbnPldkApW0tvT2[zLUBk\WyuIHzpcoUtKEeLNUC9NE4xODBzIN88US=> MonKNVI4Ojl4NEC=
HL60 cells NGPwb4REgXSxdH;4bYNqfHliYYPzZZk> NGfQbWw4OiCq MkP4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAxOSEQvF2= MmX1NlA4OzF|NUW=
SK-OV-3 M1rpU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn:yOFghcA>? NGf0ZW5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFAyOyEQvF2= MnvSNVg4OjJzMke=
HepG2 cells MWjDfZRwfG:6aXPpeJkh[XO|YYm= MlPqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEmFNUC9NE4xODBzNDFOwG0> MnGzNVcyOjdyNkG=
ZR-75-1 M4niVGN6fG:2b4jpZ4l1gSCjc4PhfS=> NVXHOotnS3m2b4TvfIlkcXS7IHHnZYlve3RiWmKtO|UuOSClZXzsJIxqdmVuIFnDOVA:OC5yMECyOEDPxE1? NXr6WnN1OTd{NEm2OFk>
HeLa cell MojjR5l1d3SxeHnjbZR6KGG|c3H5 M{\NXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEinTHGgZ4VtdCCuaX7lMEBKSzVyPUCuNFAxOyEQvF2= MnTCNVczPDl4NEm=
HCT116 cell NGTjXZpEgXSxdH;4bYNqfHliYYPzZZk> NWXmUI9TS3m2b4TvfIlkcXS7IHHnZYlve3RiSFPUNVE3KGOnbHygcIlv\SxiSVO1NF0xNjByMEO1JO69VQ>? MojoNVczPDl4NEm=
KBV1 cells MXTDfZRwfG:6aXPpeJkh[XO|YYm= M1i5TFczKGh? MlfCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO MYiyNFc{OTN3NR?=
SKOV3 MkS4R5l1d3SxeHnjbZR6KGG|c3H5 MnTHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECwOFIh|ryP M3vKNFI1ODF4MECy
SKOV3 cells M1vXVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT29XOyClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKGG|c3H5MEBIUTVyPUCuNFAxPDJizszN NWrlOGlYOjN5N{KzNFk>
HeLa cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEWxJO69VQ>? NX35WWF1OTl6N{m3OVg>
DU145 cells MY\DfZRwfG:6aXPpeJkh[XO|YYm= NWPCU5oyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN NUPMU21MOjRyMU[wNFI>
DU145 cells NGHLWnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2mw[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> M4GzflI{Pzd{M{C5
SK-N-BE M4HocHBzd2yrZnXyZZRqd25iYYPzZZk> NGDqNJk4OiCq M1[4bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU5vQlWgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMEW4JO69VQ>? NInEVWwzOjN{OUW2NS=>
NCIH460 cells Mlv3R5l1d3SxeHnjbZR6KGG|c3H5 MXu0PEBp M1TwSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUUh2NkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByME[g{txO MnfFNVg{ODN6NEm=
KB-VIN10 cells NFPBVpVRem:uaX\ldoF1cW:wIHHzd4F6 M2m4O|czKGh? M2XofGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KtWmlPOTBiY3XscJMhd3[ncj3lfJBz\XO|aX7nJHAu\3BiMUewM21FWjFiYX\0[ZIhPzJiaILzJIJ6KG2ndHj5cIVv\SCkbIXlJIF{e2G7LDDJR|UxRTBwMECwO{DPxE1? M3rvN|IyPjRzN{Cw
HCT116 cells M3jN[WN6fG:2b4jpZ4l1gSCjc4PhfS=> MkXEO|IhcA>? M{jGW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhYzOKXYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGGodHXyJFczKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR|UxRTBwMECwO|Qh|ryP MXyyNVk2PTR3NB?=
DU145 cells NYL1R2VoS3m2b4TvfIlkcXS7IHHzd4F6 NYrpepp2PDhiaB?= MlzNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxODhizszN M2XVfVE5OzB|OES5
RS4:11 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NFzjSIs4OiCq NUHQfYlESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDSV|Q7OTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JEg{NSh2LEWt[Ilu\XSqeXz0bIligm:uLUKtfYwqNTJuNT3kbZBp\W67bITleJJigm:uaYXtJIJzd22rZHWgeIV{fCxiSVO1NF0xNjByMEig{txO NFKySlAzPTd6NU[wOS=>
HCT 116 MlHVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkfGR49v[2WwdILheIlwdiC5aHnjbEBxem:mdXPld{A2OCViaX7obYJqfGmxbjDv[kBoem:5dHigc4YhcHWvYX6gZ49td25idIXtc5IhUEOWIEGxOkwhUUN3ME2wMlAxODlizszN MmXFNVE4OTR4MUO=
HeLa cells NGrDT4lEgXSxdH;4bYNqfHliYYPzZZk> NF\GXHI4OiCq NIjQOFJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFczKGi{czDifUBz\XOjeoXybY4h[mG|ZXSg[ox2d3Knc3PlcoNmKGG|c3H5MEBKSzVyPUCuNFAxQSEQvF2= MUeyOFY3QTh6OB?=
BNL 1ME A.7R.1 cells NV70d4pLS3m2b4TvfIlkcXS7IHHzd4F6 NVvwNZJNS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSk6OIEHNSUBCNjeULkGgZ4VtdHNuIFnDOVA:OC5yMEC5JO69VQ>? M4TWVVI2Pzh3NkC1
Calu6 MXzQdo9tcW[ncnH0bY9vKGG|c3H5 Ml3COFghcA>? NFXTdnhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhcJU3KGGodHXyJFQ5KGi{czDifUB{eGWldILvdIhwfG:vZYTyfUwhUUN3ME2wMlAxODl2IN88US=> M2XZ[lIyPzd2NEm5
melanoma B16 cell M4f3TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXXDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBufXKrbnWgcYVt[W6xbXGgRlE3KGOnbHygcIlv\SxiSVO1NF0xNjByMTFOwG0> NIC0[XAyOTdzNE[xNy=>
DU145 cells Mnj0R5l1d3SxeHnjbZR6KGG|c3H5 MmiyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MVyyNFQ6Pjl{Mx?=
HCT116 cells NFfOVpJRem:uaX\ldoF1cW:wIHHzd4F6 M{LIPFczKGh? Mm[xRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNUDPxE1? MXKyNVEyOjF|MB?=
HCT15 cells MXzQdo9tcW[ncnH0bY9vKGG|c3H5 NGe4dYc4OiCq MoTQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MkL2NlEyOTJzM{C=
HL60 cells NUXzdodPWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYLEcGg1PzJiaB?= Ml7iRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MoiyNlE3PjN|MUm=
A10 cells NGHUToJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnXiOFghcA>? NYDJUmtsT3Kxd4ToJIlvcGmkaYTpc44hd2ZicnH0JGEyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NInpdXQzOjB2NEG2OC=>
HUVEC cells MlfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDZNpA1QCCq MYHHdo94fGhiaX7obYJqfGmxbjDv[kBJXV[HQzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> MlntNlIxPDRzNkS=
HL60 cells MU\DfZRwfG:6aXPpeJkh[XO|YYm= MorDO|IhcA>? NUm2Rol6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NUnOfWI4OjJzM{[zNVI>
HL60 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 NYnPcmRzPzJiaB?= M4L4WmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= MVqyNlU4QDFzMR?=
NCI-H522 cells NVq3eotsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkLHOFghcA>? Mn\aS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh3MkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByMTFOwG0> M2rUNFIzQTh{MUKy
MDA-MB-435 cells MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXm0PEBp NXzkZnpkT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= M1PGUlIzQTh{MUKy
OVCAR3 MmDxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEPxO4c1QCCq MlXRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE4xODFizszN NF3DTpYzOjl6MkGyNi=>
NCI/ADR-RES cells MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXv3TJdwPDhiaB?= MWrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kwSUSULWLFV{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MX:yNlk5OjF{Mh?=
PC3 cells M1rYO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jFcVQ5KGh? MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? MofJNlI6QDJzMkK=
DU145 cells MnvoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVvmUVYzPDhiaB?= NHPk[ItIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> MWiyNlk5OjF{Mh?=
MDA-MB-231 cells NFHB[WxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYG0PEBp NX20fW1tT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NYnwfpAyOjJ7OEKxNlI>
CEM cells MX;DfZRwfG:6aXPpeJkh[XO|YYm= NFXFVG04OiCq MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NUHNTZlkOjJ4N{[yOFc>
HCT116 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= NIPjSlY4OiCq NEDZTXVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MmCyNlI3PzZ{NEe=
MDA-MB-435 cells MmfaR5l1d3SxeHnjbZR6KGG|c3H5 MWG3NkBp NGXkUFREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MX6yNlY4PjJ2Nx?=
HaCaT cells NGjObJJRem:uaX\ldoF1cW:wIHHzd4F6 NFrTWZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjhR4FVKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MXSyN|A3OzRyMR?=
HL60 cells NV3jfXd4WHKxbHnm[ZJifGmxbjDhd5NigQ>? M2faXVczKGh? NYHmeHlnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP Mnq1NlMyOTdzN{G=
HL60 cells M{i1WHBzd2yrZnXyZZRqd25iYYPzZZk> MV63NkBp M4\MTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB5MjDodpMh[nliKEOtLFQtPS2maX3leIh6dHSqaXH6c4wuOi27bDmtNkw2NWSrcHjlcpltfGW2cnH6c4xqfW1iYoLvcYll\SC2ZYP0MEBKSzVyPUCuNFAyKM7:TR?= M4Wze|I2Pzh3NkC1
HT-29 MnK3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWE0zQSClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MnjnNlU3QDlzMUG=
HL60 cells MkC3VJJwdGmoZYLheIlwdiCjc4PhfS=> MnnVO|IhcA>? MkSzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M4HpUVIxPDJyNEO5
Hs578T cells M2XIVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4HtTlQ5KGh? MX;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= NE\6RXozOjl6MkGyNi=>
HL60 cells MXnDfZRwfG:6aXPpeJkh[XO|YYm= MXi3NkBp MmPJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= M4m5c|I{PDR3NEm2
SKOV3 cells M3:1XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrOe2lIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUU0:YMzDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M{TmTVI2Pjh7MUGx
MDA-MB-468 cells NUDUOnp{S3m2b4TvfIlkcXS7IHHzd4F6 NU\FS|ZoPCCmYYnz NILLcXdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IESg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEyKM7:TR?= NEnCXXkzPDJzMEWwNy=>
MCF7 cells M4\JbHBzd2yrZnXyZZRqd25iYYPzZZk> MUi3NkBp NEfQZ5NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFzMTFOwG0> M{XyeVIzOzJ7NU[x
H460 MVzDfZRwfG:6aXPpeJkh[XO|YYm= NI[4RpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJidHXzeEwhUUN3ME2wMlAxOTJizszN NUjDXlZFOTh5OEOyNFc>
H460 Mn3NVJJwdGmoZYLheIlwdiCjc4PhfS=> M{DUXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczygTWM2OD1yLkCwNVI1KM7:TR?= M2fROFE3PzJ{NkOz
NCI-H460 cells NGC5SYxEgXSxdH;4bYNqfHliYYPzZZk> NYnyd4lsPzJiaB?= M3fKfGN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJJRme3RuIFnDOVA:OC5yMEGzJO69VQ>? NHjjVW8yQDN7Nki1Oy=>
OVCAR8 cells NV7pPFRwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYO5OkBp MnTJS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU3ZESVJ6IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHAu\2y7Y3;wdo91\WmwIHHmeIVzKDl4IHjyd{whUUN3ME2wMlAxOTNizszN NF32UmwzOjB2NEG2OC=>
NCI/ADR-RES cells NVTHWIliS3m2b4TvfIlkcXS7IHHzd4F6 NH7SS2ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= MlnONlMzOTR2NUK=
OVCAR8 cells NHXr[2pEgXSxdH;4bYNqfHliYYPzZZk> Mnu3PVYhcA>? MlHwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP MWWyOVAzPTl7MR?=
NCI/ADR-RES cells Ml\6R5l1d3SxeHnjbZR6KGG|c3H5 MnHsPVYhcA>? Mnv4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgPVYhcHK|IHL5JGdq\W2|YTDzeIFqdmmwZz3iZZNm\CCuaXfoeEBucWO{b4Pjc5B6NCCLQ{WwQVAvODBzMzFOwG0> NIrMXIwzPTB{NUm5NS=>
OVCAR8 cells NYHCfZpzS3m2b4TvfIlkcXS7IHHzd4F6 MkPOR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHL5JJRzgXCjbjDicJVmKGW6Y3z1d4lwdiCjc4PhfUwhUUN3ME2wMlAxOTNizszN NXzUWZI2OjN{MUS0OVI>
HuTu 80 cells NHz5VmtRem:uaX\ldoF1cW:wIHHzd4F6 Mn3PO|IhcA>? M1zrR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJGh2XHViOECgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUO3JO69VQ>? NGTYTVkzOjN{OUW2NS=>
K562 cells Mn;3R5l1d3SxeHnjbZR6KGG|c3H5 M2jzcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEmFNUC9NE4xODF2IN88US=> Mm\iNVk5Ozd3OUS=
NCI/ADR (MDR) cells Ml\LSpVv[3Srb36gZZN{[Xl? NEfxUVNE\WyuIHP5Z4xmKGG{cnXzeEBqdiCQQ1mvRWRTKCiPRGKpJINmdGy|IHL5JIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlMEBKSzVyPUCuNFAyPSEQvF2= M4fVe|E3Ozd5MUi3
HUVEC NY\BOWRPWHKxbHnm[ZJifGmxbjDhd5NigQ>? NIf2O4RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVENCCLQ{WwQVAvODBzNTFOwG0> M3T0eVE3PzJ{NkOz
KB cell MYnQdo9tcW[ncnH0bY9vKGG|c3H5 MojqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNQjDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= MYSxO|A{PDF2Nx?=
KB-VIN10 cell MVfQdo9tcW[ncnH0bY9vKGG|c3H5 MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHygcIlv\SCkeTDt[ZRpgWynbnWgZox2\SCmeXWgZZN{[XluIFnDOVA:OC5yMEG1JO69VQ>? NFHYS2syPzB|NEG0Oy=>
Human SH-SY5Y neuroblastoma cells MVXGeY5kfGmxbjDhd5NigQ>? MlLaTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiSIXtZY4hW0hvU2m1XUBv\XW{b3LsZZN1d22jIHPlcIx{NCCLQ{WwQVAvODBzNTFOwG0> MmPDNVU6PjN5MkK=
SW620 cells MWPQdo9tcW[ncnH0bY9vKGG|c3H5 NGDr[o04OiCq MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDpckBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyPTJizszN MVuyNlMzQTV4MR?=
Molt4/C8 cells M1\EcnBzd2yrZnXyZZRqd25iYYPzZZk> MlfqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{whUUN3ME2wMlAxOTZizszN NEnFUosyPzB|NEG1NC=>
ACHN cell NHTnZZFRem:uaX\ldoF1cW:wIHHzd4F6 MmXmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHKnc3nzeIFvfCCDQ1jOJINmdGxibHnu[UBmgHC{ZYPzbY5oKE2GUkGgZpkhSWyjbXHyJGJtfWViYYPzZZktKEmFNUC9NE4xODF4IN88US=> MWixO|I5PjN7Mx?=
Molt4/C8 cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 Mo[xN{Bl[Xm| NHvJR|ZCdnSrcILvcIln\XKjdHn2[UBm\m[nY4SgZYdicW6|dDDoeY1idiCPb3z0OE9EQCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC5yMEG2JO69VQ>? NVfkUZNHOTd2MUm2NFc>

... Click to View More Cell Line Experimental Data

In vivo In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry.[2] Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice.[3]

Protocol

Kinase Assay:[1]
- Collapse

Competitive binding assay using LC-MS/MS:

Colchicine (1.2 μ M) is incubated with tubulin (1.3 mg/mL) in the incubation buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9) at 37℃ for 1 h. Varying concentrations (0.1 − 125 μ M) of Combretastatin A4 are used to compete with colchicine originally bound to tubulin. After incubation, the filtrate is obtained. The ability of the analogue to inhibit the binding of colchicine is expressed as a percentage of control binding in the absence of any competitor.
Cell Research:[1]
- Collapse
  • Cell lines: MDA-MB-231, A549, and Hela cells
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231, A549, and HeLa cells are grown in DMEM medium (115 units/mL of penicillin G, 115 μg/mL of streptomycin, and 10% fetal bovine serum). Cells are seeded in 96-well plates (5000 cells/well) containing 50 μL of growth medium for 24 h. After medium removal, 100 μL of fresh medium containing individual analogue compounds at different concentrations is added to each well and incubated at 37 ℃ for 72 h. After 24 h of culture, the cells are supplemented with 50 μL of analogue compounds dissolved in DMSO (less than 0.25% in each preparation). After 72 h of incubation, 20 μL of resazurin is added for 2 h before recording fluorescence at 560 nm (excitation) and 590 nm (emission) using a Victor microtiter plate fluorimeter. The IC50 is defined as the compound concentration required to inhibit cell proliferation by 50% in comparison with cells treated with the maximum amount of DMSO (0.25%) and considered as 100% viability.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: FVB/N or nude NMRI female mice bearing NT2 and MDA-MB-231 tumors
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+50% PEG 300+ddH2O
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 316.35
Formula

C18H20O5

CAS No. 117048-59-6
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(C=C(C=C1)C=CC2=CC(=C(C(=C2)OC)OC)OC)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to make solution for in vivo IP injection?

  • Answer:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Combretastatin A4 | Combretastatin A4 supplier | purchase Combretastatin A4 | Combretastatin A4 cost | Combretastatin A4 manufacturer | order Combretastatin A4 | Combretastatin A4 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID